Abstract: A telemetry unit (100) is provided for mounting to the inside of a pneumatic tyre, which includes sensors for measuring the pressure and temperature within the tyre and an RF transmitter for transmitting measured data to an on-board display remote location. The unit (100) includes a piezoelectric element (114) supported in a housing (112) with an actuator (136) arranged for contact with the element (114), to deflect the element (114) in response to external forces acting on the actuator (136) during rotation of the tyre. For every rotation of the tyre, cyclic pulses of electrical charge are generated by the deflection of the element (114). The unit (100) includes control means which controls the consumption of stored charge when measuring and transmitting data and is arranged to vary the rate of transmission of data from the unit (100) in dependance on the rotary speed of the tyre.

Abstract: A telemetry unit (100) is provided for mounting inside a pneumatic tyre. The unit (100) includes a piezoelectric power generator for supplying power to the unit (100). A piezoelectric element (114) is supported in a housing (112) with an actuator 136 arranged for contact with the element (114), to deflect the element (114) in response to external forces acting on the actuator (136) during rotation of the tyre. For every rotation of the tyre, cyclic pulses of electrical charge are generated by the deflection of the element (114). The charge is stored and utilised under a power consumption protocol to operate pressure and temperature sensors and to transmit data from the unit (100). The telemetry circuitry is mounted for movement with the actuator (136) and therefore contributes to the actuating mass acting on the element (114).

Abstract: Low power consumption protocol A telemetry unit (100) is provided for mounting inside a pneumatic tyre, which includes a piezoelectric element (114) supported in a housing (112), with an actuator (136) arranged for contact with the element (114), to deflect the element (114) in response to external forces acting on the actuator (136) during rotation of the tyre. For every rotation of the tyre, cyclic pulses of electrical charge are generated by the deflection of the element (114). The charge is stored and utilised under a power consumption protocol including the steps of: initiating power to a data measurement circuit for measuring data from the environment local to the unit (100); disabling power to the data measurement circuit; initiating power to a data transmission circuit; transmitting data from the measurement circuit; and disabling power to the transmission circuit.

Abstract: Compounds of general formula (I), wherein W represents a 5- or 6-membered aromatic heterocyclic ring containing one or more non-quaternised sp2 nitrogen atoms in its ring, which heterocyclic ring may be optionally fused to a benzene ring or to a further 5- or 6-membered aromatic heterocyclic ring containing one or more nitrogen atoms, wherein at least one of the said heterocyclic rings may also contain an oxygen or sulphur atom, and wherein any of the rings may be optionally substituted with one or more substituents selected from --C.sub.1 -C.sub.6 alkyl, --OC.sub.1 -C.sub.6 alkyl, halo, --CF.sub.3 and --CN; Z represents a) a divalent alkanediyl group from 1 to 8 carbon atoms which may be a straight or branched-chain, wherein the said group is either unsubstituted or substituted by one or more substituents selected from hydroxy, --OC.sub.1 -C.sub.6 alkyl, --SC.sub.1 -C.sub.

Abstract: Compounds of general formula I: ##STR1## wherein W represents imidazo [4,5-c]pyridin-1-yl, imidazo [4,5-c]pyridin-3-yl and imidazo [4,5-c]pyridin-5-yl optionally substituted with one or more --C.sub.1 -C.sub.6 alkyl substituents; Z represents a) a divalent alkanediyl, alkenediyl or alkynediyl group; b) a --(CH.sub.2).sub.q U(CH.sub.2).sub.r -- group, optionally substituted, wherein q is an integer from 0-3, r is an integer from 0-3 and U is --O-- or --S--; Q represents a carbonyl, thiocarbonyl or sulphonyl group; B represents a) a --VR.sup.8 group wherein V is --C(.dbd.O)O-- or --CH.sub.2 O--; are antagonists of platelet activating factor (PAF).

Abstract: The present invention is directed to compounds of general formula I as well their pharmaceutically and veterinarily acceptable acid addition salts or hydrates thereof. The present invention is further directed to pharmaceutical and veterinary compositions containing the compounds of general formula I. The present compounds of general formula I are antagonist of platelet activating factor (PAF). Accordingly, the present invention is also directed to methods for preventing, treating or ameliorating in human or mammalian animals, various diseases or physiological conditions mediated by PAF.

Abstract: Compounds of the general formula I; ##STR1## wherein: A.sup.1 is .dbd.N--, .dbd.CH-- or .dbd.CR.sup.1 --;A.sup.2 is --N.dbd., --CH.dbd. or --CR.sup.2 .dbd.;provided that, when one of A.sup.1 and A.sup.2 is a nitrogen atom, the other of A.sup.1 and A.sup.2 is other than a nitrogen atom;wherein the remainder of the variables are defined in the specification;and their pharmaceutically and veterinarily acceptable acid addition salts and hydrates are antagonists of platelet activating factor (PAF) and as such are useful in the treatment or amelioration of various diseases or disorders mediated by PAF.

Abstract: The invention encompasses compounds of general formula I: ##STR1## wherein W represents an imidazo[4,5-c]pyridyl group, optionally substituted with one or more substituents selected from C.sub.1 -C.sub.6 alkyl, C.sub.1 -C.sub.6 alkoxy, halo, CF, and CN; and Z, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6 are variables. These compounds are useful as antagonists of platelet activating factor.

Abstract: This invention is a novel document preparation system in which a user is capable of viewing various permutations of a predefined portion of text. With this invention the display of variations in text is performed automatically. This provides a technique by which the developer can more quickly audit the results of his work and on the user's side it permits the user to rapidly see a wide variety of different transactions which is of enormous use to a young associate learning a particular practice area. In one embodiment, the user is provided with a subset of the total number of permutations of a particular portion of text. Various techniques are used to provide only "meaningful" variations of the text, thereby avoiding the need for the user to view what might be an extremely large number of permutations, many of which are of no real import based upon the task at hand.

Abstract: Compounds of general formula I; ##STR1## wherein: A.sup.1 is .dbd.N--, .dbd.CH-- or .dbd.CR.sup.1 --;A.sup.2 is --N.dbd., --CH.dbd. or --CR.sup.2 .dbd.;provided that, when one of A.sup.1 and A.sup.2 is a nitrogen atom, the other of A.sup.1 and A.sup.2 is other than a nitrogen atom; wherein the rest of the variables are defined in the specification; and their pharmaceutically and veterinarily acceptable acid addition salts and hydrates are antagonists of platelet activating factor (PAF) and as such are useful in the treatment of amelioration of various diseases or disorders mediated by PAF.

Abstract: Compounds of general formula I; ##STR1## wherein: A.sup.1 is .dbd.N--, .dbd.CH-- or .dbd.CR.sup.1 --;A.sup.2 is .dbd.N--, .dbd.CH-- or .dbd.CR.sup.2 --;provided that, when one of A.sup.1 and A.sup.2 is a nitrogen atom, the other of A.sup.1 and A.sup.2 is other than a nitrogen atom; wherein the other variables are as defined in the specificationand their pharmaceutically and veterinarily acceptable acid addition salts and hydrates are antagonists of platelet activating factor (PAF) and as such are useful in the treatment or amelioration of various diseases or disorders mediated by PAF.

Abstract: Compounds of general formula I; ##STR1## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8, A.sup.1, A.sup.2, B, and X are variables.These compounds are antagonists of platelet activating factor (PAF) and as such are useful in the treatment or amelioration of various diseases or disorders mediated by PAF.